Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genertec Universal Medical Group Co (HKSE:02666) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Genertec Universal Medical Group Co EBITDA Margin % Related Terms
Genertec Universal Medical Group Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genertec Universal Medical Group Co EBITDA Margin % Chart
HKSE:02666 vs V, MA, AXP: EBITDA Margin % Comparison
For the Credit Services subindustry, Genertec Universal Medical Group Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genertec Universal Medical Group Co EBITDA Margin % vs Credit Services Industry
For the Credit Services industry and Financial Services sector, Genertec Universal Medical Group Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Genertec Universal Medical Group Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genertec Universal Medical Group Co (HKSE:02666) has a EBITDA Margin % of 23.94% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Genertec Universal Medical Group Co and its competitors. This is 23% below median its historical median of 30.98. Over the past decade, Genertec Universal Medical Group Co's EBITDA Margin % has ranged from 25.01 to 46.93. According to the industry distribution chart, Genertec Universal Medical Group Co ranks #192 out of 420 companies in the Credit Services industry, placing it in the top 45.7%.
Is Genertec Universal Medical Group Co's EBITDA Margin % too high?
Genertec Universal Medical Group Co's current EBITDA Margin % of 23.94% is 23% below median its 10-year median of 30.98. Over the past 10 years, this metric has ranged from a low of 25.01 to a high of 46.93. The Credit Services industry median EBITDA Margin % is 23.19. Genertec Universal Medical Group Co's value of 23.94% is 3.3% above this industry median. Based on the distribution chart, Genertec Universal Medical Group Co ranks #192 out of 420 companies in the Credit Services industry, which is above the industry midpoint. Overall, Genertec Universal Medical Group Co has a GF Score™ of 84/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Genertec Universal Medical Group Co's EBITDA Margin % compare to V and MA?
According to the Credit Services industry distribution chart, Genertec Universal Medical Group Co ranks #192 out of 420 companies for EBITDA Margin %. This puts Genertec Universal Medical Group Co in the upper half of its industry. The industry median EBITDA Margin % is 23.19. Genertec Universal Medical Group Co's value of 23.94% is 3.3% above this benchmark. Historically, Genertec Universal Medical Group Co's own EBITDA Margin % has ranged from 25.01 to 46.93 over the past decade. While the company's 10-year median is 30.98 vs. the industry median of 23.19, Genertec Universal Medical Group Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Credit Services company?
The median EBITDA Margin % among Credit Services companies is 23.19, based on 420 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genertec Universal Medical Group Co's current EBITDA Margin % of 23.94% is 3.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Genertec Universal Medical Group Co and its competitors. For the Credit Services industry, the median EBITDA Margin % is 23.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genertec Universal Medical Group Co's current EBITDA Margin % is 23.94%, which is 23% below median its own 10-year median of 30.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genertec Universal Medical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Genertec Universal Medical Group Co (HKSE:02666) is currently considered Fairly Valued. The stock's GF Value™ is HK$4.51, compared to a current price of HK$4.67 — trading 3.5% above its estimated fair value. The current EBITDA Margin % is 23.94%, which is 23% below median its 10-year median of 30.98 and 3.3% above the Credit Services industry median of 23.19. Genertec Universal Medical Group Co's overall GF Score™ is 84/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Genertec Universal Medical Group Co (HKSE:02666), the current EBITDA Margin % is 23.94% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genertec Universal Medical Group Co (HKSE:02666) Overvalued in 2026?
Based on GuruFocus' analysis, Genertec Universal Medical Group Co stock appears to be overvalued.
The current stock price of HK$4.67 is trading 3.5% above its estimated GF Value™ of HK$4.51.
GuruFocus considers Genertec Universal Medical Group Co to be Fairly Valued.
Key valuation signals for HKSE:02666:
EBITDA Margin %: 23.94% (23% below median its 10-year median of 30.98)
GF Value™: HK$4.51 vs. price of HK$4.67 (3.5% above fair value)
Industry Position: 3.3% above the Credit Services median (#192 of 420)
No single metric tells the full story. See the HKSE:02666 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genertec Universal Medical Group Co Ltd is principally engaged in providing financing to its customers under finance lease arrangements, the provision of advisory services, the sale of medical equipment as well as leases under operating lease arrangements, and the provision of other services. The group has two business segments namely The finance business comprises direct finance leasing, sale-and-leaseback, factoring, operating leases, and advisory services; and Healthcare business comprises includes hospital group business, healthcare technology business and specialty business. Geographically, it derives a majority of its revenue from Mainland China.
84GF Score
Get the complete analysis for HKSE:02666
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02666 has been successfully added to your 
